niravFebruary 11, 2021 19
The New Report “Peptide Synthesis Market” published by Coherent Market Insights, covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
The research dives deep into the global share, size, and trends, as well as the growth rate of the
Peptide Synthesis Market to project its progress during the forecast period. Most importantly, the report further identifies the past, present, and future trends that are expected to influence the development rate of the Peptide Synthesis market. The research segments the market on the basis of product type, application, and region. To offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to
Share this article
Share this article
PISCATAWAY, N.J., Feb. 11, 2021 /PRNewswire/ GenScript USA Inc., the world s leading life science research tools and services provider,
announced today that it has received Emergency Use Authorization by the U.S. Food and Drug Administration s Center for Biologics Evaluation and Research (CBER) for use of the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in convalescent plasma screening. The cPass kit is the first FDA authorized test that specifically detects COVID-19 neutralizing antibodies without the use of live virus. Neutralizing antibodies block the ability of the virus to infect a cell and are widely recognized biomarkers of immunity.
Share this article
Share this article
PISCATAWAY, N.J., Jan. 13, 2021 /PRNewswire/ GenScript USA Inc., the world s leading research reagent provider, announced today that it has submitted an application to the U.S. Food and Drug Administration s Center for Biologics Evaluation and Research (CBER) for use of the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in convalescent plasma screening. The kit, which has been authorized by the FDA for emergency use in clinical diagnostics laboratories, is the first commercially available product to specifically detect COVID-19 neutralizing antibodies without the use of live virus. Neutralizing antibodies block the ability of the virus to infect a cell and are widely recognized biomarkers of immunity.
GenScript Granted Authorization for cPass⢠SARS-CoV-2 Neutralization Antibody Detection Test in Brazil
World s first test capable of detecting virus-blocking antibodies that can be performed in standard labs in under an hour
cPass SARS-COV-2 neutralization antibody kit by GenScript Previous Next
Newswise PISCATAWAY, NEW JERSEY, December 14, 2020 – GenScript
USA Inc., the world’s leading research reagent provider, announced today that Brazil s National Health Surveillance Agency (ANVISA) (Agência Nacional de Vigilância Sanitária) has authorized the use of the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit for detecting neutralizing antibodies. The cPass test is the first and only ANVISA authorized test for detecting neutralizing antibodies to SARS-CoV-2. Neutralizing antibodies specifically block the ability of a virus to infect a cell and are well-recognized to confer immunity.